



PATENT APPLICATION

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on July 2, 2002.

Stephen A. Slusher, Reg. No. 43,924

July 2, 2002
(Date Signed)

1627
RECEIVED
JUL 11 2002
TECH CENTER 16012900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Shubh D. Sharma, et al.

Serial No.: 10/049,718

Filed: February 13, 2002

For: Melanocortin Metallopeptide Constructs,
Combinatorial Libraries and Applications

Examiner: UNKNOWN

Group Art Unit: 1627

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT WITHIN THREE
MONTHS OF FILING OR BEFORE MAILING OF FIRST OFFICE ACTION
(37 CFR § 1.97(b))


Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office Action on the merits, whichever event occurs last. 37 CFR § 1.97(b).

Dated: July 2, 2002

By:


Stephen A. Slusher
Reg. No. 43,924
Direct line: (505) 998-6130

Attorneys for Applicant(s)
PEACOCK, MYERS & ADAMS, P.C.
P.O. BOX 26927
Albuquerque, New Mexico 87125-6927
Telephone: (505) 998-1500
Facsimile: (505) 243-2542

+

+



TECH CENTER 1400/2900
JUL 1 1 2002

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

Please type a plus sign (+) inside this box →

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	1.0 / 049.718
Filing Date	February 13, 2002
First Named Inventor	SHARMA, Shubh D.
Group Art Unit	1627
Examiner Name	
Attorney Docket Number	70025-02-US02

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
		ROYO, Miriam, et al., "S-Phenylacetamidomethyl (Phacm): an orthogonal cysteine protecting group for Boc and Fmoc solid-phase peptide synthesis strategies," J.Chem. Soc., ed: May 7, 1995; pp.1095-1102.
		GALLOP, Mark A., et al., "JOURNAL OF MEDICINAL CHEMISTRY," Vol. 37, No. 6; Applications of Combinatorial Technologies to Drug Discovery; April 29, 1994; pp. 1233-1251.

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.